Related by context. All words. (Click for frequent words.) 71 MADRS score 69 oxycodone CR 67 baseline HbA1c 67 adjunctive ABILIFY 67 TEAEs 66 adjunctive placebo 66 mcg BID 65 arterial thromboembolic events 65 generalized edema 65 PASI scores 65 EDSS scores 65 recurrent VTE 65 ALT elevation 65 log# copies mL 64 HBeAg seroconversion 64 CR nPR 64 QTcF 64 EDSS score 64 severe exacerbations 64 HbA 1c levels 64 neutrophil counts 64 glycated hemoglobin levels 64 recurrent venous thromboembolism 63 plus methotrexate 63 annualized relapse 63 ACR# response 63 dapagliflozin plus 63 liver histology 63 corticosteroid dose 63 Operative mortality 63 #.#/#.# mmHg [001] 63 PRADAXA #mg 63 cerebrovascular events 63 % CI #.#-#.# [007] 63 Hb A1C 63 mg BID 63 lumbar spine BMD 63 anemia hemoglobin 62 PREZISTA r arm 62 mg BID dose 62 morphometric vertebral fractures 62 Index CDAI 62 achieved ACR# 62 Ishak fibrosis score 62 peripheral sensory neuropathy 62 RLAI 62 elevated ALT 62 8mg/kg 62 NNT = 62 mEq L 62 binary restenosis 62 extrapyramidal symptoms 62 REMICADE monotherapy 62 -#.# mg dL [002] 62 ACR# responses 62 plus dexamethasone 62 Hypotension 62 log# reduction 62 Crohn Disease Activity 62 moderate renal impairment 62 lopinavir r arm 62 tapentadol ER 62 albumin excretion rate 62 nondiabetic patients 62 virologic breakthrough 62 definite stent thrombosis 62 mild renal insufficiency 61 nonvertebral fractures 61 CDAI score 61 hypophosphatemia 61 venlafaxine XR 61 cytogenetic response 61 fasting triglyceride levels 61 Expanded Disability Status 61 HbA1C levels 61 IRLS score 61 mL/min/#.# m 2 61 symptomatic VTE 61 CIMZIA TM 61 Flu Cy 61 nonfatal MI 61 plus MTX 61 CrCl 61 4mg/kg 61 receiving VICTRELIS 61 oral allopurinol 61 mcg QD 61 sUA 61 creatinine ratio 61 hematologic toxicity 61 certolizumab 61 SELENA SLEDAI score 61 conjunctival hyperemia 61 CI #.#-#.# [001] 61 REYATAZ r arm 61 Severe acneform rash 61 periprocedural 61 non valvular atrial 61 mg kg dose 61 ALT flares 61 solifenacin 61 receiving ISENTRESS 60 perioperative mortality 60 HbA 1c 60 NIHSS 60 adefovir treated 60 serum urate 60 fatigue asthenia 60 Infusion Reactions Severe 60 tipranavir r 60 desvenlafaxine succinate 60 serum aminotransferase levels 60 p = NS 60 laboratory abnormalities 60 Febrile neutropenia 60 TMC# r 60 IOP lowering 60 hip BMD 60 hypoperfusion 60 evaluable subjects 60 rimonabant #mg 60 lamivudine monotherapy 60 ipsilateral stroke 60 microvascular complications 60 MACCE 60 pyrexia mucositis sepsis febrile 60 ug dose 60 hypoglycemic events 60 timepoints 60 virologic response 60 HbA1c levels 60 baseline FEV 60 atheroma volume 60 % Confidence Interval 60 MCyR 60 HBeAg negative patients 60 sensory neuropathy 60 plasma HCV RNA 60 neurodevelopmental impairment 60 perioperative complications 60 NIHSS score 60 alanine aminotransferase 60 Montgomery Asberg Depression 60 HBeAg + 60 lymphocytosis 60 neutropenia dehydration dyspnea 60 CR CRu 60 tirofiban 60 virological response 60 unfractionated heparin UFH 60 leucopenia 60 hepatorenal syndrome 60 SSRI SNRI 60 postoperative mortality 60 sustained ventricular tachycardia 60 Stent thrombosis 60 Thal Dex 60 revascularizations 60 biochemical relapse 60 MIRAPEX 60 nonfatal myocardial infarction MI 60 placebo p = 59 intracranial hemorrhage ICH 59 elevated transaminases 59 HAQ DI 59 PRADAXA 59 clodronate 59 placebo dexamethasone 59 p = .# [002] 59 Tumor shrinkage 59 FOLFOX4 59 hypokalemia 59 receiving PEGINTRON 59 octreotide LAR 59 CIMZIA ™ 59 IIIa inhibitor 59 APTIVUS r 59 elevated LDH 59 VIIBRYD 59 complete cytogenetic response 59 DAS# remission 59 noncardiovascular mortality 59 SCr 59 serum urate levels 59 receiving golimumab 59 #mg dose [002] 59 LVEF 59 placebo fluoxetine 59 intravitreal injections 59 #mg/day [002] 59 mg/m2 dose 59 CVD mortality 59 unstable angina pectoris 59 tolterodine ER 59 COPD exacerbation 59 NATRECOR R 59 oxycodone IR 59 TAXUS p value 59 ejection fractions 59 abdominal pain abdominal discomfort 59 gout flares 59 salmeterol fluticasone 59 FDA defined valvulopathy 59 #mg BID [001] 59 serum creatinine levels 59 ATACAND 59 mcg albinterferon alfa 2b 59 intracerebral hemorrhage 59 EXJADE 59 placebo p 59 dizziness nausea diarrhea 59 neurologic dysfunction 59 YMRS 59 ACTEMRA TM 59 mild renal impairment 59 mutated KRAS 59 thrombosis embolism 59 HDRS 59 dyslipidaemia 59 discontinuations due 59 % CI #.#-#.# [006] 59 MULTAQ 59 abdominal pain flatulence 59 lopinavir r 59 partial onset seizures 59 postoperative complication 59 linaclotide treated 59 reinfarction 59 ximelagatran 59 receiving INTRON 59 hypomagnesemia 59 recurrent ischemia 59 hemoglobin A1c HbA1c 59 XIENCE V PROMUS Stent 59 mRS 59 Erythropoietic therapies may 58 mcg kg REBETOL 58 apnea hypopnea 58 affective psychosis 58 mcg linaclotide 58 abnormal p# biomarker 58 ruboxistaurin 58 log# IU mL 58 Partial Responses 58 XIENCE V demonstrated 58 events MACE 58 titrated glipizide 58 serologically active patients 58 serum sodium 58 serum uric acid 58 clinically meaningful improvement 58 UACR 58 atrophic gastritis 58 leukopenia 58 SUVmax 58 severe neutropenia 58 Kaplan Meier estimates 58 Target Lesion Revascularization TLR 58 placebo PBO 58 Hb A1c 58 Scale EDSS score 58 pulmonary exacerbation 58 CDAI 58 confidence interval #.#-#.# 58 diastolic BP 58 asthma exacerbation 58 systolic dysfunction 58 myocardial infarctions 58 thromboembolic events 58 nadroparin 58 splenectomized patients 58 mg ustekinumab 58 P = .# 58 nadolol 58 relapsed MM 58 ALT elevations 58 Arch Intern Med 58 Ejection Fraction 58 artery stenosis 58 PSADT 58 HbA 1C 58 QTc prolongation 58 periprocedural MI 58 methotrexate monotherapy 58 Elitek 58 intravascular hemolysis 58 % AST SGOT 58 x ULN 58 CDI recurrence 58 sotalol 58 % CI #.#-#.# [003] 58 subscore 58 HBeAg 58 infliximab monotherapy 58 poor metabolizers 58 serum HCV RNA 58 thrombotic complications 58 hippocampal atrophy 58 nodular partial response 58 mmHg diastolic 58 pruritis 58 abdominal distention 58 cerebrovascular accident 58 NIH CPSI 58 T2 lesions 58 baseline A1C 58 CCyR 58 mg simvastatin 58 metastatic carcinoid tumors 58 beta blocker therapy 58 aged ≥ 58 lymphopenia 58 Viread Emtriva Sustiva 58 subclinical hypothyroidism 58 ischemia driven 58 SGPT 58 divalproex sodium 58 #mg/day [001] 58 NYHA Class II 58 FluCAM arm 58 ARB telmisartan 58 virologic failure 58 mTSS 58 angiographic outcomes 58 mL sec 58 budesonide pMDI 58 NPH insulin 58 pg ml 58 psychiatric comorbidities 57 5-FU/LV 57 carotid stenosis 57 glycosylated hemoglobin HbA1c 57 plasma cortisol 57 mcg mL 57 CsA 57 atherogenic dyslipidemia 57 ULORIC 57 serum potassium 57 suboptimal adherence 57 serum estradiol 57 symptomatic intracranial 57 variceal bleeding 57 BPRS PSS 57 BARACLUDE ® 57 #mg BID [003] 57 ischemic cardiomyopathy 57 Psoriasis Area 57 primidone 57 p ≤ 57 treatment naive genotype 57 Rating Scale MADRS 57 serum sodium levels 57 β blocker 57 VT VF 57 anastomotic leak 57 extrapyramidal disorder 57 febrile neutropenia 57 moderately emetogenic 57 #.#mg/dL 57 hypoglycemic episodes 57 MMSE score 57 receiving SIMPONI 57 Clinically significant 57 rosuvastatin #mg 57 ng dL 57 hematologic adverse 57 Castration Resistant Prostate Cancer 57 nondepressed 57 divalproex 57 oral diclofenac 57 sustained virological response 57 advanced adenoma 57 concomitant AEDs 57 postintervention 57 TMP SMX 57 MoxDuo TM IR 57 UPDRS scores 57 IBDQ 57 calculated creatinine clearance 57 macroalbuminuria 57 chlorambucil 57 generalized tonic clonic seizures 57 ribavirin therapy 57 rebleeding 57 timepoint 57 platelet reactivity 57 undetectable HBV DNA 57 postoperative AF 57 umol L 57 mg TID 57 blood Phe 57 urate lowering therapy 57 dose atorvastatin 57 pooled comparator 57 undetectable HCV RNA 57 baseline serum creatinine 57 glycated hemoglobin HbA1c 57 ARCOXIA 57 ARIXTRA 57 hyperprolactinemia 57 patients undergoing CABG 57 QTc intervals 57 NMIBC 57 mCi kg 57 LV dysfunction 57 overt nephropathy 57 % CI #.#-#.# [008] 57 nonfatal stroke 57 neurologic sequelae 57 -#.# mg dL [001] 57 events SAEs 57 postprocedure 57 interferon ribavirin 57 recurrent DVT 57 cerebrovascular accidents 57 TNF antagonist 57 fasting plasma glucose FPG 57 glomerular filtration 57 resuscitated cardiac arrest 57 Median PFS 57 serum triglycerides 57 IFN alfa 57 NYHA functional class 57 NYHA class 57 haematologic 57 thrombocytopenic 57 thromboembolism 57 androgen suppression 57 events TEAEs 57 OSAHS 57 underwent CABG 57 Y BOCS 57 spontaneous bowel movements 57 incontinence episodes 57 vertebral fracture 57 pulmonary capillary wedge 57 Virologic failure 57 #mmHg [001] 57 subsyndromal 57 atrioventricular block 57 clinically meaningful reductions 57 serum phosphate levels 57 thromboembolic complications 57 tryptophan depletion 57 hyperphenylalaninemia HPA due 57 QTc 57 venous thromboembolic events 57 somatostatin analog 57 PREZISTA r 57 prolonged QT interval 57 serum cortisol 57 highly emetogenic 57 perioperatively 57 Scale EDSS 57 Thrombocytopenia 57 q#h 57 non splenectomized 57 dalteparin 57 plus OBT 57 biologic DMARD 57 revascularization procedures 57 Lupuzor ™ 57 hematological adverse 57 humanized interleukin 6 57 gadolinium enhancing lesions 57 R# #mg BID 57 rizatriptan 57 OAB symptoms 57 nicardipine 57 cGy 57 prolactin levels 57 PREZISTA ritonavir 57 Heavy menstrual bleeding 57 CSBMs 57 stage IIIB 57 histologically confirmed 57 polyp recurrence 56 p = #.# [003] 56 RECIST criteria 56 Am J Cardiol 56 PegIFN RBV 56 thromboembolic 56 peginterferon alfa 2a 56 μmol L 56 valvular disease 56 inflammatory lesions 56 femoral neck BMD 56 Serious adverse reactions 56 A1c levels 56 nonadherence 56 receiving XGEVA 56 Timed Walk 56 Relapsing Multiple Sclerosis 56 systemic embolism 56 Capacity FVC 56 nonarteritic anterior ischemic optic 56 CIMZIA TM certolizumab pegol 56 PLX STROKE targeting 56 gastric pH 56 hypoglycaemic episodes 56 dopaminergic therapy 56 nocturnal hypoglycaemia 56 fibrinolysis 56 STRIDE PD 56 BENICAR HCT 56 PSA nadir 56 β blockers 56 Platelet counts 56 atorvastatin #mg 56 systemic corticosteroid 56 cardiovascular hospitalization 56 refractory ischemia 56 ‰ ¥ 56 Kaplan Meier analysis 56 undergoing coronary angiography 56 lymphocyte count 56 mg Proellex 56 p = ns 56 estimated glomerular filtration 56 serum phosphate 56 rectal tenesmus 56 acute myocardial infarction MI 56 HOMA IR 56 quetiapine XR 56 psychiatric comorbidity 56 nausea photophobia 56 hyperglycaemia 56 NYHA Class III 56 foveal thickness 56 transaminase elevations 56 achieved statistical significance 56 #mg/m# [001] 56 neutropaenia 56 sustained virologic response 56 hepatitis C genotype 56 thrombocytopenic patients 56 piperacillin tazobactam 56 mg/# h 56 nighttime awakenings 56 cytopenias 56 coronary revascularization procedures 56 HAM D# 56 del 5q MDS 56 Postoperative complications 56 malperfusion 56 fluticasone salmeterol 56 stable angina 56 pCR 56 BPH Symptom Score 56 confidence intervals CIs 56 aminotransferases 56 serum clusterin levels 56 primary generalized tonic 56 hsCRP levels 56 serum testosterone 56 vaginal hysterectomy 56 virological failure 56 tapentadol IR 56 aldosterone antagonist 56 dose cytarabine 56 fasting plasma glucose 56 aortic insufficiency 56 COZAAR 56 abacavir lamivudine 56 -#.# log# 56 Exacerbations 56 Index CDAI score 56 diabetes mellitus DM 56 BPH symptoms 56 eplerenone 56 prednisone prednisolone plus 56 RLS symptoms 56 postoperative bleeding 56 A1C levels 56 Pharmacokinetic parameters 56 seropositive patients 56 spontaneous bacterial peritonitis 56 statistically significant p = 56 serum IGF 56 cardiovascular hospitalizations 56 GnRH agonist 56 candesartan cilexetil 56 cilostazol 56 IPSS 56 symptomatic intracranial hemorrhage 56 QD dosing 56 myocardial infarction MI 56 mg QD 56 serum ALT 56 abciximab 56 hours postdose 56 aminotransferase elevations greater 56 pulmonary exacerbations 56 Cmax 56 benazepril 56 irbesartan 56 graft dysfunction 56 blood Phe levels 56 ischemic complications 56 paresthesias 56 naïve HCV 56 myocardial infarction stroke 56 HBeAg positive patients 56 hemoglobin A1c levels 56 recurrent myocardial infarction 56 serum HBV DNA 56 LEXIVA r 56 #.#/#.# mm Hg [003] 56 unresectable HCC 56 Natalizumab 56 PAOD 56 ACR# ACR# 56 evaluable patients 56 symptomatic hyponatremia 56 euthyroid 56 ARCALYST ® 56 Viral load 56 EDARBI 56 invasive aspergillosis 56 nocturnal awakenings 56 mg dosed twice 56 fatal myocardial infarction 56 DAS# [002] 56 partial remissions 56 prednisone prednisolone 56 biochemical recurrence 56 Score DAS# 56 albumin excretion 56 nonresponders 56 severe hypoglycemic 56 CMV infection 56 cerebral vasospasm 56 hemodynamic instability 56 hyperkalemia 56 % CI #.#-#.# [005] 56 androgen deprivation 56 NSTEMI 56 posttreatment 56 haemorrhagic stroke 56 preintervention 56 ug kg 56 generalized seizures 56 Adefovir 55 mmHg p = 55 sUA levels 55 Betaferon R 55 dysmenorrhoea 55 Knodell necroinflammatory score 55 hyperbilirubinemia 55 q#d 55 stent thromboses 55 ADHD RS 55 serum PTH 55 renal artery stenosis 55 MADRS 55 acromegalic patients 55 #.#/#.# mmHg [002] 55 parkinsonian symptoms 55 nonfatal myocardial infarction 55 follicular lymphomas 55 Fasting blood glucose 55 lamivudine refractory patients 55 treatment emergent AEs 55 inhospital mortality 55 Serious AEs 55 del 5q 55 serum phosphorus 55 insulin detemir 55 detrusor overactivity 55 hepatotoxicity 55 intracranial bleeding 55 remission CR 55 pegIFN 55 Baseline characteristics 55 ALND 55 syncopal 55 detectable HCV RNA 55 doxazosin 55 CYPHER Stent 55 incidence ≥ 55 dose statin therapy 55 aspartate aminotransferase AST 55 CK # plasma concentrations 55 IU mL 55 candesartan 55 oral FTY# 55 Primary endpoints 55 % CI #.#-#.# [004] 55 bivalirudin monotherapy 55 left ventricular systolic 55 indapamide 55 LEXIVA 55 malignant neoplasm 55 % CI #.#-#.# [001] 55 silent ischemia 55 alanine aminotransferase ALT 55 DLTs 55 CHD CVD 55 ziprasidone 55 deep venous thromboses 55 venous thromboembolic 55 Myelosuppression 55 upper gastrointestinal bleeding 55 coagulopathy 55 lumbar spine bone 55 nonfasting triglyceride levels 55 prodromal symptoms 55 rufinamide 55 CIN3 55 T2DM 55 dexmedetomidine 55 PaO 2 55 diastolic hypertension 55 myocardial fibrosis 55 Acute Decompensated Heart Failure 55 fraction LVEF 55 splenectomized 55 pT3 55 VELCADE melphalan 55 mg qd 55 dysuria 55 femoral shaft fracture 55 angiotensin converting enzyme inhibitor 55 experienced virologic failure 55 TNF alpha IL 55 CI #.#-#.# [002] 55 nephrotoxicity 55 intracerebral hemorrhages 55 HCV genotype 55 mcg kg 55 GOUT 55 TLUS 55 adrenal insufficiency 55 REYATAZ ritonavir 55 #.#ng/ml 55 aspartate aminotransferase 55 atazanavir ritonavir 55 oral antidiabetic medication 55 antidiabetic medication 55 Events MACE 55 p = .# [001] 55 mucosal healing 55 target vessel revascularization 55 coronary stenosis 55 achieved CCyR 55 Relapsing Remitting Multiple Sclerosis 55 Myocardial Infarction Study 55 thrombocytosis 55 nonsignificant difference 55 AVODART 55 mg dose 55 hematological toxicity 55 receiving Vectibix monotherapy 55 RAPTIVA 55 non menstrual pelvic 55 nontraumatic 55 Oral Fingolimod 55 adalimumab 55 uncontrolled asthma 55 microalbuminuria 55 oxcarbazepine 55 Thrombolysis 55 pericardial effusions 55 Lamictal XR 55 events AEs 55 angiographic restenosis 55 neuropathy sensory 55 hypervolemic 55 thrombotic events 55 #mg doses [002] 55 SVR# 55 mmol l 55 Toxicities 55 μg kg 55 macrovascular 55 severe renal impairment 55 myocardial infarction ventricular fibrillation 55 prespecified secondary 55 HBV DNA 55 depressive symptomatology 55 AZOR 55 discontinuations 55 ibandronate 55 dyspareunia 55 systolic BP 55 femoral neck fracture 55 coronary revascularization 55 tolvaptan 55 intravenous diuretics 55 systolic hypertension 55 DAS# CRP 55 refractory NSCLC 55 confidence interval CI 55 mg d 55 ecchymosis 55 hemorrhagic complications 55 cerebral infarctions 55 neutropenic fever 55 quetiapine 55 recurrent malignant glioma 55 systemic hypotension 55 serum lipid levels 55 -#.# ± [002] 55 angiotensin converting enzyme inhibitors 55 ADHF 55 proteinuria 55 APTIVUS ritonavir 55 HF hospitalization 55 flutamide 55 viral titers 55 symptomatic atrial fibrillation 55 adenoma recurrence 55 primary aldosteronism 55 Peg IFN 55 salmeterol HFA MDI 55 systemic corticosteroids 55 cerebral infarction 55 urinary albumin excretion 55 RAPAFLO R 55 liver enzymes ALT 55 NATRECOR ® 55 interleukin IL -6 55 RBC transfusion 55 death reinfarction 55 ertapenem 55 hemoptysis 55 bosentan 55 HCV SPRINT 55 comparator arm 55 T2 lesion volume 55 thyrotropin levels 55 μg dose 55 #.#g/day 55 Treatment emergent adverse 55 adriamycin 55 weekly CSBMs 55 bleeding pallor 55 Pred Forte 55 6MWD 55 FOLPI 55 baseline LDH 55 mesalamine granules 55 mm Hg systolic 55 hypoxemia 54 enalapril 54 stomatitis pharyngitis 54 Score TOS 54 acute myocardial infarction AMI 54 metformin monotherapy 54 EFFEXOR XR 54 creatinine clearance 54 myocardial infarctions MIs 54 peripheral edema 54 corticosteroid therapy 54 brivaracetam 54 Double Blind Randomized 54 efavirenz EFV 54 elevated serum creatinine 54 ID TLR 54 mL/min/#.# m2 54 platelet inhibition 54 recurrent UTI 54 MMSE scores 54 mycophenolate mofetil 54 fluoxetine paroxetine 54 decompensated heart failure 54 phonophobia 54 multivariate adjustment 54 glycosylated hemoglobin levels 54 PSVT 54 recurrent glioblastoma multiforme 54 atherosclerotic renal artery stenosis 54 asymptomatic carotid stenosis 54 Ann Intern Med 54 refractory AML 54 mg p = 54 Asymptomatic 54 underwent resection 54 IV NSCLC 54 multivariable adjusted 54 cryptogenic 54 receiving prophylactic anticoagulation 54 Ischemic 54 achieved mucosal healing 54 underwent surgical resection 54 Virologic 54 leukocyte count 54 Severity MSCS score 54 QRS duration 54 Partial Response 54 ventricular tachyarrhythmia 54 dyspnea 54 somnolence headache 54 alemtuzumab treated 54 nephrectomy 54 aminotransferase ALT 54 LV ejection fraction 54 treat NNT 54 Raptiva r 54 KRAS mutations occur 54 Postoperative 54 CCR5 tropic HIV 54 low dose Iluvien 54 -#.# log# copies mL 54 Serum creatinine 54 hypercalcemia 54 quetiapine risperidone 54 ocular adverse 54 HCV RESPOND 2 54 UPDRS 54 cholecystitis 54 angina pectoris 54 ≥ 54 pmol L 54 ADAS cog 54 paresthesia 54 antiarrhythmic drug 54 advanced adenomas 54 fluid overload 54 FOLFIRI 54 achieving PASI 54 angiographically 54 mU liter 54 antiretroviral naïve 54 nasopharyngitis 54 probable stent thrombosis 54 mg XP# 54 PROMACTA 54 apnea hypopnea index 54 Eur J Neurol 54 nonvertebral fracture 54 familial AF 54 rCBF 54 tenecteplase 54 Chronic Migraine 54 HER2 overexpression 54 dose cohort 54 seropositivity 54 iPTH 54 HAMD 54 complete cytogenetic 54 repeat revascularization 54 QTc interval 54 esomeprazole 54 venlafaxine Effexor 54 uncoated stent 54 plasma glucose levels 54 NNRTI resistance 54 nonoperative treatment 54 Myocardial infarction 54 glycoprotein IIb IIIa inhibitor 54 5-fluorouracil/leucovorin 54 Retreatment 54 affective psychoses 54 ARICEPT 54 gout flare 54 mildly symptomatic 54 CI -#.# 54 ventricular dysfunction 54 salivary flow 54 ADCS ADL 54 agomelatine 54 lipid lowering drugs 54 ropivacaine 54 unresectable stage 54 endophthalmitis 54 plasma leptin 54 acute gout flares 54 virologic response EVR 54 neonatal morbidity 54 MIs 54 eszopiclone 54 tamsulosin 54 rFVIIa 54 serum calcium levels 54 nephrotoxic drugs 54 inhospital 54 colesevelam HCl 54 allele frequencies 54 STN stimulation 54 paraprotein 54 pimecrolimus cream 54 pancreatic resection 54 dysthymia 54 secondary efficacy endpoint 54 AUA Symptom Score 54 serum phosphorous 54 neurologic deficits 54 macrovascular events 54 INFERGEN 54 corrected QT interval 54 HIV uninfected 54 nausea dizziness vomiting 54 postdischarge 54 antibody titer 54 Helicobacter pylori eradication 54 subtrochanteric 54 CHD mortality 54 fosamprenavir